Regulation
Rules, guidance and how the agencies work.
Stories
-
FDA withdraws approval of 37 ANDAs
The agency is withdrawing approval of 37 abbreviated new drug applications from multiple applicants. The applicants notified the FDA that the drug products were no longer marketed and requested the approvals be withdrawn.
-
FDA issues priority review voucher for ZANVASTRO
FDA approved ZANVASTRO on September 3, 2026. FDA issued a priority review voucher to the sponsor, Ionis Pharmaceuticals, Inc., after determining the product meets the criteria under the FD&C Act.
-
FDA classifies hematopoietic cell enrichment kit as class II device
The order designates the kit as a class II device with special controls. The special controls will be part of the codified language for classification of the hematopoietic cell enrichment kit.
-
FDA classifies infant pulse rate and oxygen saturation monitor as class II
The order assigns the device to class II, adding special controls to the codified language. The action is expected to enhance patients' access to beneficial innovative devices by reducing regulatory burdens.
-
FDA requests public comments on ibogaine trial design
FDA is opening a docket to receive comments on design elements for early-phase trials of ibogaine drug products, with a deadline of November 20, 2026. The request follows guidance issued July 14, 2026 and seeks input on dose selection, safety monitoring, eligibility criteria and other protocol elements.
-
FDA issues priority review voucher for FAYUVI (rebisufligene etisparvovec-hopf)
The FDA announced that it has awarded a priority review voucher to the sponsor of FAYUVI, a gene therapy approved on September 17, 2026. The voucher is granted to Ultragenyx Pharmaceutical Inc. for this rare pediatric disease product that meets the criteria under the FD&C Act.
-
FDA determines pralidoxime chloride AUTOINJECTOR not withdrawn for safety or effectiveness
FDA has determined that pralidoxime chloride AUTOINJECTOR solution, 600 mg/2 mL (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to approve abbreviated new drug applications for the product if other requirements are met.
-
FDA classifies focused ultrasound system as class II
The Food and Drug Administration issued a final order classifying the focused ultrasound system for non-thermal, mechanical tissue ablation into class II with special controls, effective October 6, 2026. The order codifies the classification in 21 CFR 878.4405 and identifies the special controls that will provide reasonable assurance of safety and effectiveness.
-
FDA finalizes class II status for hyperoxia monitoring device adjunct to pulse oximetry
The FDA issued a final order on October 6, 2026, classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II with special controls. The order, effective October 6, 2026, codifies the classification that was first applied on October 12, 2023.
-
FDA finalizes exemption for certain class II clinical toxicology test systems
The FDA issued a final order exempting specific class II clinical toxicology test systems from premarket notification (510(k)) requirements, effective October 6, 2026. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.
-
FDA seeks public input to support ibogaine research
The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.
-
EMA Management Board highlights September 2026 meeting
The EMA Management Board reviewed its mid-year report and progress on new pharmaceutical legislation during the September 2026 meeting. It noted 29 new human medicine applications, seven veterinary applications, and that the Clinical Trials Information System has supported more than 14,000 trials with over 200 new applications each month.